Nutriband Inc (NTRB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$5.58-8.31%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · NTRB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 219.4% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -47.9% |
Growth built into the price is above our model estimate.
The price assumes 267.4 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 117 industry peers
Why it matters: Revenue fell from $622K to $438K year over year. Growth would show more progress toward commercializing the patch.
Supportive ifRevenue in 2027-Q3 is above $438K, the reported 2027-Q2 level.
Worry ifRevenue in 2027-Q3 is at or below $438K.
Why it matters: FDA review is a stated step for the lead patch. A cleared name and label would move this step forward.
Supportive ifThe FDA approves the proposed brand name and product label for the fentanyl patch.
Worry ifThe FDA rejects the proposed name or label, or asks for changes that delay approval.
Why it matters: Losses are still large, but they have narrowed. Another drop would show progress on cost control.
Supportive ifThe Dec. 9, 2026 earnings report shows operating loss below $0.89M.
Worry ifThe report shows an operating loss of $0.89M or more.
Why it matters: Nutriband remains loss-making and relies on credit-line funding. Tighter terms could raise pressure to find more cash.
Worry ifThe company says it has less access to its credit line, tougher repayment terms, or needs more funding.
Less concerning ifThe next earnings update confirms it still has access to its credit line and needs no more funding.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$286 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $694 loss on $10,000 · 6.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,386 loss on $10,000 · 53.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The patch still needs clinical testing and FDA approval before it can reach the U.S. market. A trial start would mark progress.
Supportive ifNutriband says a clinical trial for its AVERSA fentanyl patch has begun.
Worry ifThe next earnings update reports no trial start and gives no firm trial timeline.